Current Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with Thiazolidinediones

Overview

Journal PPAR Res

Publisher Wiley

Date 2016 Jun 18

PMID 27313601

Citations 17

Authors

D Aleman-Gonzalez-Duhart

F Tamay-Cach

S Alvarez-Almazan

J E Mendieta-Wejebe

Affiliations

Soon will be listed here.

Abstract

The present review summarizes the current advances in the biochemical and physiological aspects in the treatment of type 2 diabetes mellitus (DM2) with thiazolidinediones (TZDs). DM2 is a metabolic disorder characterized by hyperglycemia, triggering the abnormal activation of physiological pathways such as glucose autooxidation, polyol's pathway, formation of advance glycation end (AGE) products, and glycolysis, leading to the overproduction of reactive oxygen species (ROS) and proinflammatory cytokines, which are responsible for the micro- and macrovascular complications of the disease. The treatment of DM2 has been directed toward the reduction of hyperglycemia using different drugs such as insulin sensitizers, as the case of TZDs, which are able to lower blood glucose levels and circulating triglycerides by binding to the nuclear peroxisome proliferator-activated receptor gamma (PPARγ) as full agonists. When TZDs interact with PPARγ, the receptor regulates the transcription of different genes involved in glucose homeostasis, insulin resistance, and adipogenesis. However, TZDs exhibit some adverse effects such as fluid retention, weight gain, hepatotoxicity, plasma-volume expansion, hemodilution, edema, bone fractures, and congestive heart failure, which limits their use in DM2 patients.

Citing Articles

Dose-response technique combined with stable isotope tracing for drug metabolite profiling by using high-resolution mass spectrometry.

Lin I, Chuang C, Shih C Front Pharmacol. 2023; 14:1293540.

PMID: 38155901 PMC: 10753831. DOI: 10.3389/fphar.2023.1293540.

Miller and Its Flavonoids, an Important Source of Products for the Treatment of Diabetes Mellitus: In Vivo and In Silico Evaluations.

Calzada F, Valdes M, Martinez-Solis J, Velazquez C, Barbosa E Pharmaceuticals (Basel). 2023; 16(5).

PMID: 37242507 PMC: 10222912. DOI: 10.3390/ph16050724.

GVS-12 attenuates non-alcoholic steatohepatitis by suppressing inflammatory responses PPARγ/STAT3 signaling pathways.

Wang Y, Zhang X, Yuan B, Lu X, Zheng D, Zhang K RSC Adv. 2022; 9(17):9555-9564.

PMID: 35520738 PMC: 9062151. DOI: 10.1039/c8ra10178g.

and Evaluation of 1,3-Thiazolidine-2,4-Dione Derivatives as Euglycemic Agents.

Aleman-Gonzalez-Duhart D, Alvarez-Almazan S, Valdes M, Tamay-Cach F, Elena Mendieta-Wejebe J PPAR Res. 2022; 2021:5100531.

PMID: 35003235 PMC: 8741387. DOI: 10.1155/2021/5100531.

Commonly Prescribed and Over-the-Counter Drugs as Secondary Causes of Osteoporosis-Part One.

Pizzorno J, Pizzorno L Integr Med (Encinitas). 2021; 20(2):8-15.

PMID: 34377089 PMC: 8325490.

References

Grygiel-Gorniak B . Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review. Nutr J. 2014; 13:17. PMC: 3943808. DOI: 10.1186/1475-2891-13-17. View

Bays H . Adiposopathy is "sick fat" a cardiovascular disease?. J Am Coll Cardiol. 2011; 57(25):2461-73. DOI: 10.1016/j.jacc.2011.02.038. View

Dos Santos J, Bernardes A, Giampietro L, Ammazzalorso A, De Filippis B, Amoroso R . Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/γ. J Struct Biol. 2015; 191(3):332-40. DOI: 10.1016/j.jsb.2015.07.006. View

Scheen A, Esser N, Paquot N . Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control. Diabetes Metab. 2015; 41(3):183-94. DOI: 10.1016/j.diabet.2015.02.003. View

Cheung B, Li C . Diabetes and hypertension: is there a common metabolic pathway?. Curr Atheroscler Rep. 2012; 14(2):160-6. PMC: 3314178. DOI: 10.1007/s11883-012-0227-2. View

Cariou B, Hanf R, Lambert-Porcheron S, Zair Y, Sauvinet V, Noel B . Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care. 2013; 36(10):2923-30. PMC: 3781493. DOI: 10.2337/dc12-2012. View

Zhang L, Ren X, Wan B, Guo L . Structure-dependent binding and activation of perfluorinated compounds on human peroxisome proliferator-activated receptor γ. Toxicol Appl Pharmacol. 2014; 279(3):275-283. DOI: 10.1016/j.taap.2014.06.020. View

Wahli W, Michalik L . PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab. 2012; 23(7):351-63. DOI: 10.1016/j.tem.2012.05.001. View

Petersen R, Christensen K, Assimopoulou A, Frette X, Papageorgiou V, Kristiansen K . Pharmacophore-driven identification of PPARγ agonists from natural sources. J Comput Aided Mol Des. 2010; 25(2):107-16. DOI: 10.1007/s10822-010-9398-5. View

10.

Jia J, Ye T, Cui P, Hua Q, Zeng H, Zhao D . AP-1 transcription factor mediates VEGF-induced endothelial cell migration and proliferation. Microvasc Res. 2016; 105:103-8. PMC: 4836857. DOI: 10.1016/j.mvr.2016.02.004. View

11.

Kim T, Yang Q . Peroxisome-proliferator-activated receptors regulate redox signaling in the cardiovascular system. World J Cardiol. 2013; 5(6):164-74. PMC: 3691497. DOI: 10.4330/wjc.v5.i6.164. View

12.

Zhang H, Ding C, Lai Z, Chen S, Devasthale P, Herpin T . Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists. Bioorg Med Chem Lett. 2015; 25(6):1196-205. DOI: 10.1016/j.bmcl.2015.01.066. View

13.

Soltesova Prnova M, Ballekova J, Gajdosikova A, Gajdosik A, Stefek M . A novel carboxymethylated mercaptotriazinoindole inhibitor of aldose reductase interferes with the polyol pathway in streptozotocin-induced diabetic rats. Physiol Res. 2015; 64(4):587-91. DOI: 10.33549/physiolres.933034. View

14.

Alex S, Lange K, Amolo T, Grinstead J, Haakonsson A, Szalowska E . Short-chain fatty acids stimulate angiopoietin-like 4 synthesis in human colon adenocarcinoma cells by activating peroxisome proliferator-activated receptor γ. Mol Cell Biol. 2013; 33(7):1303-16. PMC: 3624264. DOI: 10.1128/MCB.00858-12. View

15.

Ahmadian M, Suh J, Hah N, Liddle C, Atkins A, Downes M . PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 2013; 19(5):557-66. PMC: 3870016. DOI: 10.1038/nm.3159. View

16.

Garcia-Rojas P, Antaramian A, Gonzalez-Davalos L, Villarroya F, Shimada A, Varela-Echavarria A . Induction of peroxisomal proliferator-activated receptor gamma and peroxisomal proliferator-activated receptor gamma coactivator 1 by unsaturated fatty acids, retinoic acid, and carotenoids in preadipocytes obtained from bovine white adipose.... J Anim Sci. 2010; 88(5):1801-8. DOI: 10.2527/jas.2009-2579. View

17.

Hulsmans M, Geeraert B, Arnould T, Tsatsanis C, Holvoet P . PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression. PLoS One. 2013; 8(4):e62253. PMC: 3631170. DOI: 10.1371/journal.pone.0062253. View

18.

Karasova M, Soltesova Prnova M, Stefek M . A novel zwitterionic inhibitor of aldose reductase interferes with polyol pathway in ex vivo and in vivo models of diabetic complications. Pharmazie. 2015; 69(10):747-51. View

19.

Kroker A, Bruning J . Review of the Structural and Dynamic Mechanisms of PPARγ Partial Agonism. PPAR Res. 2015; 2015:816856. PMC: 4578752. DOI: 10.1155/2015/816856. View

20.

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35(6):1364-79. PMC: 3357214. DOI: 10.2337/dc12-0413. View